Voriconazole for Fungal Infections
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
Recruiting
Phase 2
Interventional Study
Fungal Infection
Haematological Malignancy
Blood Cancer
Infectious Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 2 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 104 (estimated)
- Sponsor
- The University of Queensland · Other
Who this trial is looking for
This trial is looking for children and adults who have blood cancer or a fungal infection. Participants will take a medication called voriconazole, and their doses will be adjusted based on their genetic testing.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 2 years old.
- I have given my written consent to join the trial.
- I have been prescribed voriconazole.
- I can attend appointments at a trial site or have enough follow-up appointments.
You may not be able to join if
- I have had a stem cell transplant without access to pre-transplant DNA.
- I am likely to die within 7 days.
- I have been part of this trial before.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally effective dosing regimens. This study investigates if voriconazole increases the proportion of patients achieving therapeutic exposure at day 8 of dosing compared with stand…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 2 years.
* Written informed consent obtained.
* Decision to prescribe voriconazole.
* Admitted to a trial site, or sufficient outpatient follow-up appointments are feasible
Exclusion Criteria:
* Post-allogeneic haematopoietic stem cell transplant (HCT) patient, without…
Contacts